Novanta Inc. exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very conservative debt profile (Debt/Equity 0.23). However, the company is severely overvalued based on deterministic metrics, with a current price of $128.85 dwarfing the Graham Number ($34.91) and Intrinsic Value ($11.61). While the earnings track record is stellar with consistent beats over 25 quarters, the massive trailing P/E of 87.65 and bearish insider selling by the CEO and CFO create significant valuation risk. The stock is currently a high-quality business trading at a speculative premium.